CCL2 and pulmonary fibrosis: Based upon clinical and experimental characterizations of cellular and molecular responses in human IPF, specifically exaggerated CCL2 expression [62], [66]–[68], we have presented data, which indicate that AFSC attenuate increased CCL2 in BAL in an experimental model of lung fibrosis.